The CYP19 TTTA Repeat Polymorphism Is Related to the Prognosis of Premenopausal Stage I—II and Operable Stage III Breast Cancers

CME Activity Information
Release Date:
Date Credit Expires:
Time to Complete:	1 hour
Medium:	Internet Online
*Click here to learn more about our review process.

Instructions for Participation

1. Read the following information before beginning the educational activity and click the "Take this course" link at the bottom of the page
2. Study the educational activity
3. Complete the CME quiz and evaluation
4. After successful completion of the CME quiz and evaluation, you will receive the credit or participation certificate

*The CME quiz and evaluation must be completed by  in order to receive the credit or participation certificate.

Target Audience:

Learning Objectives

1. Describe why premenopausal women with the long allele of the CYP19 TTTA repeat polymorphism have a greater survival rate and may not gain benefit from adjuvant chemotherapy.
2. Assess whether we need to revisit the routine use of adjuvant chemotherapy in high-risk premenopausal patients with the long allele of the CYP19 polymorphism.
3. Explain why further validation in a randomized study with a large sample size is needed to determine whether the CYP19 TTTA repeat polymorphism can serve as a predictor in hormone receptor—positive premenopausal patients.

Accreditation and Credit Designation

The School of Medicine of The University of North Carolina at Chapel Hill designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Disclosure Policy

All information is submitted and reviewed and found to be scientifically rigorous, based on the best available evidence, fair and balanced, and free of commercial bias. All the recommendations involving clinical medicine in this CME activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported or used in CME in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection and analysis.

Any potential conflicts of interests are resolved via The Oncologist's anonymous peer review process. All manuscripts are reviewed by the Editorial Board with ad hoc assistance from external experts in the field. All final publication decisions are made by the Editorial Board. The acceptance of a manuscript is based on its originality and importance to the field as assessed by the Editors.

Author Disclosure(s)

Section Editors Disclosures

CME Activity Director Disclosure

Independent Peer Reviewers and Staff Managers Disclosures

Commercial Support

Hardware/Software Requirements

Other Links

Correspondence

• Take this course